Lupin Limited

Lupin Limited functions as a global pharmaceutical enterprise, dedicated to the research, development, production, marketing, and distribution of a broad spectrum of products. These include both proprietary and generic drug formulations, biotechnology products, and active pharmaceutical ingredients (APIs), catering to markets within India and internationally. The company's therapeutic offerings span numerous medical fields, such as cardiovascular diseases, diabetology, asthma, pediatrics, central nervous system conditions, gastrointestinal disorders, anti-infectives, nonsteroidal anti-inflammatory drug (NSAID) therapy, respiratory ailments, women's health, and anti-tuberculosis treatments. Beyond these, Lupin also provides biosimilar medications, over-the-counter (OTC) products, and specialized pharmaceuticals. It actively invests in drug discovery and development programs, with a particular focus on oncology, immunology, and metabolic disorders, alongside conducting bio clinical research activities. The company's operational infrastructure encompasses a network of laboratories, LupiMitra collection centers, and convenient pick-up points. Established in 1968, the company was originally known as Lupin Chemicals Limited, adopting its current name, Lupin Limited, in 2001. Its corporate headquarters are situated in Mumbai, India.

CEO: Vinita D. Gupta - https://www.lupin.com